Compare HIFS & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIFS | DRTS |
|---|---|---|
| Founded | 1834 | 2015 |
| Country | United States | Israel |
| Employees | 92 | 125 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 682.4M | 546.5M |
| IPO Year | N/A | N/A |
| Metric | HIFS | DRTS |
|---|---|---|
| Price | $275.98 | $6.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 48.1K | ★ 291.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $209.71 | $2.30 |
| 52 Week High | $338.00 | $8.60 |
| Indicator | HIFS | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 39.16 | 44.44 |
| Support Level | $258.88 | $6.57 |
| Resistance Level | $297.56 | $7.77 |
| Average True Range (ATR) | 12.87 | 0.48 |
| MACD | -3.76 | -0.16 |
| Stochastic Oscillator | 19.23 | 17.83 |
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.